News & Events
Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences
Crinetics' company management will participate in the TD Cowen 45th Annual Healthcare Conference on March 3, and the Leerink Global...
READ MORECrinetics Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 105,100 shares of its common stock and granted an...
READ MORECrinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
Event Date: February 27, 2025
READ MORECrinetics to Report Fourth Quarter and Full Year 2024 Financial Results
Event Date: February 27, 2025
READ MORECrinetics Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Crinetics granted non-qualified stock option awards to purchase an aggregate of 146,400 shares of its common stock to sixteen new...
READ MORECrinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia
Event Date: January 10, 2025
READ MORECrinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
Crinetics announces positive topline results from an open-label, Phase 2 congenital adrenal hyperplasia (CAH) study of atumelnant, a candidate being...
READ MORECrinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Crinetics to present at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on Tuesday, January...
READ MORECrinetics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Event Date: January 14, 2025
READ MORETransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.